View Future GrowthRapid Dose Therapeutics 과거 순이익 실적과거 기준 점검 0/6Rapid Dose Therapeutics 의 수입은 연평균 -6.6%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 17.6%의 비율로 증가해 왔습니다.핵심 정보-6.57%순이익 성장률0.13%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률17.61%자기자본이익률n/a순이익률-157.17%최근 순이익 업데이트30 Nov 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.공시 • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.공시 • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.공시 • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.공시 • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.공시 • Oct 31Rapid Dose Therapeutics Corp. announced that it has received CAD 0.851 million in fundingOn October 30, 2024. the company has closed the final tranche of the transaction공시 • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.공시 • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.공시 • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.공시 • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.공시 • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.공시 • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.매출 및 비용 세부 내역Rapid Dose Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:RDTC.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비30 Nov 253-44031 Aug 253-54031 May 252-55028 Feb 252-55030 Nov 242-64031 Aug 241-54031 May 241-53029 Feb 241-43030 Nov 231-43031 Aug 231-32031 May 231-33028 Feb 231-43030 Nov 221-95031 Aug 221-105031 May 221-95028 Feb 222-85030 Nov 212-23031 Aug 212-22031 May 212-12028 Feb 211-22030 Nov 200-22031 Aug 20-1-53031 May 200-54029 Feb 200-87030 Nov 190-177031 Aug 191-157031 May 190-146028 Feb 190-113030 Nov 180-32031 Aug 180-220양질의 수익: RDTC.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: RDTC.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RDTC.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 6.6% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RDTC.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RDTC.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RDTC.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 22:57종가2026/06/08 00:00수익2025/11/30연간 수익2025/02/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rapid Dose Therapeutics Corp.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Peter-Thilo HaslerSphene Capital GmbH
공시 • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.
공시 • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
공시 • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.
공시 • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
공시 • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.
공시 • Oct 31Rapid Dose Therapeutics Corp. announced that it has received CAD 0.851 million in fundingOn October 30, 2024. the company has closed the final tranche of the transaction
공시 • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.
공시 • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.
공시 • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.
공시 • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.
공시 • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.
공시 • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.